[go: up one dir, main page]

AR072458A2 - Derivados de azol-pirimidina condensados, composiciones farmaceuticas que los contienen y su uso para inhibir la actividad pi3k-? - Google Patents

Derivados de azol-pirimidina condensados, composiciones farmaceuticas que los contienen y su uso para inhibir la actividad pi3k-?

Info

Publication number
AR072458A2
AR072458A2 ARP090102458A ARP090102458A AR072458A2 AR 072458 A2 AR072458 A2 AR 072458A2 AR P090102458 A ARP090102458 A AR P090102458A AR P090102458 A ARP090102458 A AR P090102458A AR 072458 A2 AR072458 A2 AR 072458A2
Authority
AR
Argentina
Prior art keywords
amino
alkyl
optionally substituted
alkoxycarbonyl
halogen
Prior art date
Application number
ARP090102458A
Other languages
English (en)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of AR072458A2 publication Critical patent/AR072458A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un derivado de azolpirimidina condensado de la formula (1), su forma tautomérica o estereoisomérica, o una sal del mismo, donde X representa NH; Y1 representa N; Y2 e Y3 representan CR3R4; el enlace químico entre Y2- - -Y3 representa un enlace simple; Z3 y Z4 representan CH; Z1 y Z2 representan independientemente CH o CR2; R1 representa: uno de los siguientes anillos heterocíclicos seleccionados del grupo que consiste en: pirazolilo sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en hidroxi, halogeno, nitro, ciano, carboxi, amino, N-(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, N-(alcoxicarbonil C1-6)amino, N-(formil)-N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino (alquenil C2-6)amino, N-(alcansulfonil C1-6)amino, N-[N,N-di(alquil C1-6)amino metilen]amino, alquiltio C1-6, alcanosulfonilo C1-6, sulfamoilo, alcoxi C1-6, alcoxicarbonilo C1-6, pirrolilo, imidazolilo, pirazolilo, pirrolidinilo, piridilo, fenil alcoxicarbonilo C1-6, tiazolilo opcionalmente sustituido con piridilo, piperazinilo opcionalmente sustituido con alquilo C1-6 o alcoxi C1-6; o con 1 o 2 sustituyentes alquilo C1-6 sustituidos con mono-, di- o tri-halogeno; o con 3 sustituyentes alquilo C1-6 opcionalmente sustituidos con mono-, di- o tri- halogeno; furilo sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en hidroxi, halogeno, nitro, ciano, carboxi, amino, N-(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino. N-(alcoxicarbonil C1-6)amino, N-(formil)-N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino (alquenil C2-6)amino, N-(alcan C1-6)sulfonil amino, N-[N,N-di(alquil C1-6)aminometilen]amino, alquiltio C1-6, alcansulfonilo C1-6, sulfamoilo, alcoxi C1-6, alcoxicarbonilo C1-6, pirrolilo, imidazolilo, pirazolilo, pirrolidinilo, piridilo, fenil alcoxicarbonilo C1-6, tiazolilo opcionalmente sustituido con piridilo, piperazinilo opcionalmente sustituido con alquilo C1-6 o alcoxi C1-6 y alquilo C1-6 opcionalmente sustituido con mono, di- o tri-halogeno, tienilo sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en hidroxi, halogeno (aunque no cloro), carboxi, amino, N-(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, N-(alcoxicarbonil C1-6)amino, N-(formil)-N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino (alquenil C2-6)amino, N-(alcan C1-6)sulfonil amino, N-[N,N-di(alquil C1-6)aminometilen]amino, alquiltio C1-6, alcansulfonilo C1-6, sulfamoilo, alcoxi C1-6, alcoxicarbonilo C1-6, pirrolilo, imidazolilo, pirazolilo, pirrolidinilo, piridilo, fenil alcoxicarbonilo C1-6, tiazolilo opcionalmente sustituido con piridilo, piperazinilo opcionalmente sustituido con alquilo C1-6 o alcoxi C1-6; o con 1 sustituyente alquilo C1-6 sustituido con mono-, di- o tri-halogeno; o con 2 o 3 sustituyentes alquilo C1-6 opcionalmente sustituidos con mono-, di- o tri-halogeno; tiazolilo sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en hidroxi, halogeno, nitro, ciano, carboxi, amino, N-(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, N-(formil)-N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino (alquenil C2-6)amino, N-(alcan C1-6)sulfonil amino, N-[N,N-di(alquil C1-6)aminometilen]amino, alquiltio C1-6, alcansulfonilo C1-6, sulfamoilo, alcoxi C1-6, alcoxicarbonilo C1-6, pirrolilo, imidazolilo, pirazolilo, pirrolidinilo, piridilo, fenil alcoxicarbonilo C1-6, tiazolilo opcionalmente sustituido con piridilo, piperazinilo opcionalmente sustituido con alquilo C1-6, o alcoxi C1-6 y alquilo C1-6 opcionalmente sustituido con mono-, di- o tri-halogeno; o con 1 o 2 sustituyentes alquilo C1-6 sustituido con mono-, di- o tri-halogeno; o con 3 sustituyentes alquilo C1-6 opcionalmente sustituidos con mono-, di- o tri-halogeno; o con 3 sustituyentes piridilo; o con 3 sustituyentes N-(alcoxicarbonil C1-6)amino; isotiazolilo opcionalmente sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en hidroxi, halogeno, nitro, ciano, carboxi, amino, N-(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, N-(alcoxicarbonil C1-6)amino, N-(formil)-N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino (alquenil C2-6)amino, N-(alcan C1-6)sulfonil amino, N-[N,N-di(alquil C1-6)aminometilen]amino, alquiltio C1-6, alcansulfonilo C1-6, sulfamoilo, alcoxi C1-6, alcoxicarbonilo C1-6, pirrolilo, imidazolilo, pirazolilo, pirrolidinilo, piridilo, fenil alcoxicarbonilo C1-6, tiazolilo opcionalmente sustituido con piridilo, piperazinilo opcionalmente sustituido con alquilo C1-6 o alcoxi C1-6 y alquilo C1-6 opcionalmente sustituido con mono-, di- o tri-halogeno; oxazolilo opcionalmente sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en hidroxi, halogeno, nitro, ciano, carboxi, amino, N-(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, N-(alcoxicarbonil C1-6)amino, N-(formil)-N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino (alquenil C2-6)amino, N-(alcan C1-6)sulfonil amino, N-[N,N-di(alquil C1-6)aminometilen]amino, alquiltio C1-6, alcansulfonilo C1-6, sulfamoilo, alcoxi C1-6, alcoxicarbonilo C1-6, pirrolilo, imidazolilo, pirazolilo, pirrolidinilo, piridilo, fenil alcoxicarbonilo C1-6, tiazolilo opcionalmente sustituido con piridilo, piperazinilo opcionalmente sustituido con alquilo C1-6 o alcoxi C1-6 y alquilo C1-6 opcionalmente sustituido con mono-, di- o tri-halogeno; isoxazoliIo sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en hidroxi, halogeno, nitro, ciano, carboxi, amino, N-(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, N-(alcoxicarbonil C1-6)amino, N-(formil)-N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino (alquenil C2-6)amino, N-(alcan C1-6)sulfonil amino, N-[N,N-di(alquil C1-6)aminometilen]amino, alquiltio C1-6, alcansulfonilo C1-6, sulfamoilo, alcoxi C1-6, alcoxicarbonilo C1-6, pirrolilo, imidazolilo, pirazolilo, pirrolidinilo, piridilo, fenil alcoxicarbonilo C1-6, tiazolilo opcionalmente sustituido con piridilo, piperazinilo opcionalmente sustituido con alquilo C1-6 o alcoxi C1-6; o con 1 o 2 sustituyentes alquilo C1-6 sustituidos con mono-, di- o tri-halogeno; o con 3 sustituyentes alquilo C1-6 opcionalmente sustituidos con mono-, di- o tri-halogeno; imidazolilo sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en hidroxi, halogeno, nitro, ciano, carboxi, amino, N-(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, N-(alcoxicarbonil C1-6)amino, N-(formil)-N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino (alquenil C2-6)amino, N-(alcan C1-6)sulfonil amino, N-[N,N-di(alquil C1-6)aminometilen]amino, alquiltio C1-6, alcansulfonilo C1-6, sulfamoilo, alcoxi C1-6, alcoxicarbonilo C1-6 , pirrolilo, imidazolilo, pirazolilo, pirrolidinilo, piridilo, fenil alcoxicarbonilo C1-6, tiazolilo opcionalmente sustituido con piridilo, piperazinilo opcionalmente sustituido con alquilo C1-6 o alcoxi C1-6 y alquilo C1-6 opcionalmente sustituidos con mono-, di- o tri-halogeno; isoimidazolilo opcionalmente sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en hidroxi, halogeno, nitro, ciano, carboxi, amino, N-(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, N-(alcoxicarbonil C1-6)amino, N-(formil)-N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino (alquenil C2-6)amino, N-(alcan C1-6)sulfonil amino, N-[N,N-di(alquil C1-6)aminometilen]amino, alquiltio C1-6, alcansulfonilo C1-6, sulfamoilo, alcoxi C1-6, alcoxicarbonilo C1-6, pirrolilo, imidazolilo, pirazolilo, pirrolidinilo, piridilo, fenil alcoxicarbonilo C1-6, tiazolilo opcionalmente sustituido con piridilo, piperazinilo opcionalmente sustituido con alquilo C1-6 o alcoxi C1-6 y alquilo C1-6 opcionalmente sustituido con mono-, di- o tri-halogeno; 1,2,3-tiadiazolilo sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en hidroxi, halogeno, nitro, ciano, carboxi, amino, N-(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, N-(alcoxicarbonil C1-6)amino, N-(formil)-N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino (alquenil C2-6)amino, N-(alcan C1-6)sulfonil amino, N-[N,N-di(alquil C1-6)aminometilen]amino, alquiltio C1-6, alcansulfonilo C1-6, sulfamoilo, alcoxi C1-6, alcoxicarbonilo C1-6, pirrolilo, imidazolilo, pirazolilo, pirrolidinilo, piridilo, fenil alcoxicarbonilo C1-6, tiazolilo opcionalmente sustituido con piridilo, piperazinilo opcionalmente sustituido con alquilo C1-6 o alcoxi C1-6 y alquilo C1-6 opcionalmente sustituido con mono-, di- o tri-halogeno; 1,2,4-tiadiazolilo, 1,2,5-tiadiazolilo o 1,3,4-tiadiazolilo opcionalmente sustituidos con 1 a 3 sustituyentes seleccionados del grupo que consiste en hidroxi, halogeno, nitro, ciano, carboxi, amino, N-(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, N-(alcoxicarbonil C1-6)amino, N-(formil)-N-(alquil C1-6)amino, N,N-di(alquil C1-6)amino (alquenil C2-6)amino, N-(alcan C1-6)sulfonil amino, N-[N,N-di(alquil C1-6)aminometilen]amino, alquiltio C1-6, alcansulfonilo C1-6, sulfamoilo, alcoxi C1-6, alcoxicarbonilo C1-6, pirrolilo, imidazolilo, pirazolilo, pirrolidinilo, piridilo, fenil alcoxicarbonilo C1-6, tiazolilo opcionalmente sustituido con piridilo, piperazinilo opcionalmente sustituido con alquilo C1-6 o alcoxi C1-6 y alquilo C1-6 opcionalmente sustituido con mono-, di- o tri-halogeno; 1,2,3-oxadiazolilo, 1,2,4-oxadiazolilo, 1,2,5-oxadiazolilo o 1,3,4-oxadiazolilo, opcionalmente sustituidos con 1 a 3 sustituyentes seleccionados del grupo que consiste en hidroxi, halogeno, nitro, ciano, carboxi, amino, N-(alquil C1-6)amino, N-(hidroxialquil C1-6)amino, N,N-di(alquil C1-6)amino, N-(acil C1-6)amino, N-(alcoxicarbonil C1-6)amino, N-(formil)-N-(alquil C1-6)amino,
ARP090102458A 2002-09-30 2009-07-01 Derivados de azol-pirimidina condensados, composiciones farmaceuticas que los contienen y su uso para inhibir la actividad pi3k-? AR072458A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02021861 2002-09-30

Publications (1)

Publication Number Publication Date
AR072458A2 true AR072458A2 (es) 2010-09-01

Family

ID=32039115

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030103542A AR041426A1 (es) 2002-09-30 2003-09-29 Derivados de azol-pirimidina condensados; uso del compuesto para la preparacion de medicamentos
ARP090102458A AR072458A2 (es) 2002-09-30 2009-07-01 Derivados de azol-pirimidina condensados, composiciones farmaceuticas que los contienen y su uso para inhibir la actividad pi3k-?

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP030103542A AR041426A1 (es) 2002-09-30 2003-09-29 Derivados de azol-pirimidina condensados; uso del compuesto para la preparacion de medicamentos

Country Status (32)

Country Link
US (2) US7511041B2 (es)
EP (2) EP1549652B1 (es)
JP (1) JP4790266B2 (es)
KR (1) KR101059652B1 (es)
CN (1) CN100384846C (es)
AR (2) AR041426A1 (es)
AT (2) ATE411996T1 (es)
AU (1) AU2003293310B2 (es)
BR (1) BRPI0314830B8 (es)
CA (1) CA2499134C (es)
CY (2) CY1109790T1 (es)
DE (1) DE60324296D1 (es)
DK (2) DK1549652T3 (es)
EC (2) ECSP055768A (es)
ES (2) ES2312843T3 (es)
HR (2) HRP20131159B1 (es)
IL (1) IL166855A (es)
MA (1) MA27483A1 (es)
MX (1) MXPA05001808A (es)
MY (1) MY140756A (es)
NO (1) NO331457B1 (es)
NZ (1) NZ539062A (es)
PE (1) PE20050089A1 (es)
PL (1) PL226562B1 (es)
PT (2) PT2042504E (es)
RU (1) RU2326881C9 (es)
SI (2) SI1549652T1 (es)
TW (1) TWI327570B (es)
UA (1) UA82205C2 (es)
UY (1) UY28001A1 (es)
WO (1) WO2004029055A1 (es)
ZA (1) ZA200503306B (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CN102976984B (zh) 2003-08-29 2015-04-08 三井化学株式会社 农园艺用杀虫剂的制备中间体
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
RU2403258C2 (ru) 2004-10-07 2010-11-10 Бёрингер Ингельхайм Интернациональ Гмбх Тиазолилдигидроиндазолы
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
EP3211093A1 (en) 2005-04-14 2017-08-30 The Trustees of Boston University Diagnostic for lung disorders using class prediction
BRPI0614188A2 (pt) * 2005-07-29 2011-03-15 4Sc Ag compostos inibidores heterocìclicos de nf-kappab, uso dos mesmos e composição farmacêutica
CA2645310A1 (en) 2006-03-09 2007-09-13 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
EP2041139B1 (en) * 2006-04-26 2011-11-09 F. Hoffmann-La Roche AG Pharmaceutical compounds
WO2008064244A2 (en) * 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP1953163A1 (en) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
WO2008148023A2 (en) * 2007-05-23 2008-12-04 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating neurological disorders
EP2217590A4 (en) * 2007-09-17 2011-12-14 Glaxosmithkline Llc Pyridopyrimidine derivatives as PI3-kinase inhibitors
CA2700200A1 (en) 2007-09-19 2009-03-26 The Trustees Of Boston University Identification of novel pathways for drug development for lung disease
US8859572B2 (en) * 2008-01-14 2014-10-14 Bayer Intellectual Property Gmbh Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
WO2009111547A1 (en) * 2008-03-04 2009-09-11 Wyeth 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
JPWO2009128520A1 (ja) * 2008-04-18 2011-08-04 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する複素環化合物
US20110212053A1 (en) * 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
EP2168582A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2356120B1 (en) * 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
AU2009314760B2 (en) * 2008-11-11 2011-11-10 Je Il Pharmaceutical Co.,Ltd Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
ES2674719T3 (es) 2008-11-13 2018-07-03 Gilead Calistoga Llc Terapias para neoplasias hematológicas
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
MX2011011036A (es) 2009-04-20 2012-01-20 Gilead Calistoga Llc Metodos de tratamiento para tumores solidos.
ES2644724T3 (es) * 2009-04-30 2017-11-30 Glaxo Group Limited Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
JP6078339B2 (ja) 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド 甲状腺状態の診断のための方法および組成物
KR20120049281A (ko) 2009-07-21 2012-05-16 길리아드 칼리스토가 엘엘씨 Ｐｉ３ｋ 억제제를 이용한 간 장애의 치료
JP2013504325A (ja) * 2009-09-09 2013-02-07 アビラ セラピューティクス， インコーポレイテッド Ｐｉ３キナーゼインヒビターおよびその使用
CN102958540B (zh) * 2010-04-16 2015-09-02 拜耳知识产权有限责任公司 含取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AP2013006834A0 (en) 2010-10-01 2013-04-30 Bayer Ip Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
CN103370320B (zh) * 2010-11-11 2016-04-27 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
US9730943B2 (en) 2010-11-11 2017-08-15 Bayer Intellectual Property Gmbh Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EP2968537A1 (en) 2013-03-15 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
US9999623B2 (en) 2013-04-08 2018-06-19 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
MA42164B1 (fr) 2013-05-01 2019-12-31 Hoffmann La Roche Composes biheteroaryle et leurs utilisations
WO2015027431A1 (en) * 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
CA2934534A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
JP2017502021A (ja) 2013-12-20 2017-01-19 ギリアード カリストガ エルエルシー ホスファチジルイノシトール３−キナーゼ阻害剤のためのプロセス方法
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
JP6867295B2 (ja) 2015-03-09 2021-04-28 バイエル ファーマ アクチエンゲゼルシャフト 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
EP3426657B1 (en) * 2016-03-08 2022-07-13 Bayer Pharma Aktiengesellschaft 2 amino n [7 methoxy 2, 3-dihydroimidazo-[1, 2-c]quinazolin-5-yl]pyrimidine 5 carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
JP2019532922A (ja) 2016-09-23 2019-11-14 バイエル ファーマ アクチエンゲゼルシャフト Ｐｉ３ｋ−阻害剤の組み合わせ
WO2018112176A1 (en) 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
CA3054249A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
WO2019048527A1 (en) 2017-09-08 2019-03-14 Bayer Pharma Aktiengesellschaft COPANLISIB FORMULATIONS
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
EP3694511A1 (en) 2017-10-13 2020-08-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment of pancreatic cancer
WO2019101871A1 (en) 2017-11-23 2019-05-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) A new marker for predicting the sensitivity to pi3k inhibitors
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
WO2020020385A1 (zh) * 2018-07-27 2020-01-30 上海翰森生物医药科技有限公司 含三并环类衍生物抑制剂、其制备方法和应用
CN109053554B (zh) * 2018-08-01 2020-07-28 江苏八巨药业有限公司 一种使用催化剂合成3-乙酰吡啶的方法
WO2020043617A1 (en) 2018-08-28 2020-03-05 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
WO2020078788A1 (en) 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
CN114621236B (zh) * 2022-04-25 2024-06-18 河南湾流生物科技有限公司 一种喹啉类饲料添加剂的制备方法
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644354A (en) * 1968-09-16 1972-02-22 Sandoz Ag 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4287341A (en) 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
NZ234186A (en) * 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
CN1033644C (zh) * 1993-01-02 1996-12-25 瑞安大药厂股份有限公司 3-取代甲基-2，3-二氢咪唑并[1，2-c]喹唑啉衍生物，其制备与用途
EP0771204A4 (en) 1994-08-12 1999-10-20 Pro Neuron Inc METHOD FOR TREATING SEPSIS OR FLAMMABLE DISEASES WITH OXYPURINE NUCLEOSIDES
US6066642A (en) * 1996-01-29 2000-05-23 The United States Of America As Represented By The Department Of Health And Human Services Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
US5932584A (en) * 1997-05-06 1999-08-03 National Science Council Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof
EP1278748B1 (en) 2000-04-25 2011-03-23 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives

Also Published As

Publication number Publication date
KR20050067404A (ko) 2005-07-01
PL226562B1 (pl) 2017-08-31
KR101059652B1 (ko) 2011-08-25
ES2312843T3 (es) 2009-03-01
EP2042504A1 (en) 2009-04-01
ES2367141T3 (es) 2011-10-28
HRP20131159B1 (hr) 2019-11-01
NZ539062A (en) 2007-05-31
CY1109790T1 (el) 2014-09-10
AU2003293310B2 (en) 2010-04-01
TW200413379A (en) 2004-08-01
US20090270388A1 (en) 2009-10-29
CN1688582A (zh) 2005-10-26
BRPI0314830B8 (pt) 2021-05-25
ZA200503306B (en) 2006-07-26
HRP20050375B1 (hr) 2014-03-14
PL375935A1 (en) 2005-12-12
US7511041B2 (en) 2009-03-31
RU2326881C2 (ru) 2008-06-20
IL166855A (en) 2014-05-28
DE60324296D1 (de) 2008-12-04
DK2042504T3 (da) 2011-09-19
MY140756A (en) 2010-01-15
EP2042504B1 (en) 2011-06-01
NO331457B1 (no) 2012-01-09
RU2326881C9 (ru) 2009-04-10
ECSP055768A (es) 2005-08-11
SI1549652T1 (sl) 2009-04-30
BRPI0314830B1 (pt) 2018-03-27
CY1112174T1 (el) 2015-12-09
DK1549652T3 (da) 2009-02-23
UY28001A1 (es) 2004-04-30
CN100384846C (zh) 2008-04-30
JP2006508063A (ja) 2006-03-09
MXPA05001808A (es) 2005-08-16
AR041426A1 (es) 2005-05-18
MA27483A1 (fr) 2005-08-01
BR0314830A (pt) 2005-08-16
US8129386B2 (en) 2012-03-06
EP1549652A1 (en) 2005-07-06
RU2005113165A (ru) 2005-10-10
CA2499134A1 (en) 2004-04-08
WO2004029055A1 (en) 2004-04-08
AU2003293310A1 (en) 2004-04-19
SI2042504T1 (sl) 2011-10-28
US20060128732A1 (en) 2006-06-15
JP4790266B2 (ja) 2011-10-12
CA2499134C (en) 2011-12-20
HRP20131159A2 (hr) 2014-05-23
UA82205C2 (en) 2008-03-25
ECSP11005768A (es) 2011-03-31
PE20050089A1 (es) 2005-04-20
TWI327570B (en) 2010-07-21
HK1084393A1 (zh) 2006-07-28
HRP20050375A2 (en) 2006-05-31
EP1549652B1 (en) 2008-10-22
PT2042504E (pt) 2011-09-07
ATE411996T1 (de) 2008-11-15
PT1549652E (pt) 2008-12-15
ATE511510T1 (de) 2011-06-15
NO20052076L (no) 2005-04-27

Similar Documents

Publication Publication Date Title
AR072458A2 (es) Derivados de azol-pirimidina condensados, composiciones farmaceuticas que los contienen y su uso para inhibir la actividad pi3k-?
RU2416603C9 (ru) Производные аминодигидротиазина
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
PE20090641A1 (es) Amidas heterociclicas
NO20031065L (no) Spiroheterocykliske nitriler nyttige som reversible inhibitorer av cysteinproteaser
SI2279737T1 (sl) Heterociklične spojine, učinkovite kot inhibitorji beta-laktamaz
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
AR040408A1 (es) Derivados de benzotiadiazepina, procesos para su preparacion y composiciones farmaceuticas que los contienen
CY1110358T1 (el) Υποκατεστημενα παραγωγα προπενυλ πιπεραζινης ως νεοι αναστολεις της αποακετυλασης ιστονης
AR031613A1 (es) Derivados de piridina, un medicamento, una composicion farmaceutica, un inhibidor de la quinasa betaikappab, un medicamento anti-inflamatorio, un inmunosupresor, un medicamento para la isquemia, un medicamento anti-tumoral y el uso de dichos derivados para la preparacion de un medicamento
EA200401200A1 (ru) Карбониламинопроизводные как новые ингибиторы гистондеацетилазы
NO20080917L (no) Nytt heterocyklidenacetamidderivat
NO20091394L (no) Pyridin-4-yl-derivater som immunmodulerende midler
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
WO2008109177A3 (en) Metalloprotease inhibitors containing a heterocyclic moiety
CO6231028A2 (es) Compuestos y composiciones como inhibidores de la proteina quinasa
DK1268471T3 (da) N-heterocykliske derivater som NOS-inhibitorer
ATE432272T1 (de) Aminophenylderivate als neue inhibitoren von histondeacetylase
DE60219521D1 (de) Aryloxyphenyl und arylsulfanylphenylderivate
WO2009010789A3 (en) Pyrimidine derivatives 934
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
WO2004014868A3 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
MXPA05007519A (es) Nuevos derivados de la purina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion.
EA200600601A1 (ru) Производные аминопиридина в качестве ингибиторов индуцируемой no-синтазы

Legal Events

Date Code Title Description
FC Refusal